• Joshua W D Tobin, Greg Hapgood, Anna Johnston, Chan Y Cheah, Sze T Lee, Judith Trotman, Shafqat Inam, Belinda A Campbell, Debbie Norris, Michael MacManus, Mark Hertzberg, and Eliza Hawkes.
• Princess Alexandra Hospital, Brisbane, Queensland, Australia.
• Intern Med J. 2024 Aug 1; 54 (8): 138413951384-1395.

AbstractFollicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma subtype, accounting for 15-20% of all lymphoma diagnoses. Although typically slow-growing and responsive to frontline therapies, advanced-stage FL remains incurable with current treatments and typically follows a chronic relapsing/remitting course with increasingly shorter responses to subsequent lines of therapy. Outcomes are highly variable; some patients experience prolonged first remissions that may approximate a 'functional cure'. By contrast, a significant minority of patients experience disease progression shortly after frontline treatment resulting in high rates of lymphoma-related mortality. Reflecting on the heterogeneous natural history of FL, clinical practice varies widely, particularly in controversial areas, including appropriate disease staging, selection of management strategies and duration of clinical follow-up. This position statement presents an evidence-based synthesis of the literature for application in Australasian practice.© 2024 Royal Australasian College of Physicians.

16 keywords...

hide…